New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 26, 2013
07:06 EDTMACKMerrimack's MM-121 demonstrates positive signal in two Phase 2 studies
Merrimack Pharmaceuticals announced the results of two Phase 2 studies evaluating MM-121 in the treatment of women with ER/PR+, HER2 negative breast cancer. One study was conducted in metastatic breast cancer, or mBC, in combination with exemestane. The second was conducted in the neoadjuvant setting in combination with paclitaxel followed by doxorubicin and cyclophosphamide. MM-121 is a monoclonal antibody designed to target the ErbB3, or HER3, receptor and to interfere with growth factor-mediated resistance to standard-of-care therapies.
News For MACK From The Last 14 Days
Check below for free stories on MACK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 8, 2014
08:08 EDTMACKMerrimack says ferumoxytol well tolerated in diagnostic imaging study
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use